SUVEN PHARMACEUTICALS share price has plunged 3% and is presently trading at Rs 894.3.
Meanwhile, the BSE HEALTHCARE index is at 40,216.8 (up 0.1%).
Among the top losers in the BSE HEALTHCARE index today are AARTI DRUGS (down 3.7%) and FORTIS HEALTHCARE (down 2.4%).
FDC (up 5.9%) and ASTER DM HEALTHCARE (up 2.9%) are among the top gainers today.
Over the last one year, SUVEN PHARMACEUTICALS has moved up from Rs 485.8 to Rs 894.3, registering a gain of Rs 408.5 (up 84.1%).
On the other hand, the BSE HEALTHCARE index has moved up from 26,901.6 to 40,216.8, registering a gain of 49.5% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Cadila Healthcare (up 98.7%), Lupin (up 98.4%) and Jubilant Pharmova (up 96.5%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 81,373.6 (up 0.1%).
The top gainers among the BSE Sensex today are L&T (up 2.7%) and Bajaj Finserv (up 1.4%). The most traded stocks in the BSE Sensex are Tata Steel and SBI.
In the meantime, NSE Nifty is at 24,857.0 (up 0.1%). BPCL and Divis Laboratories are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,355.7 to 81,373.6, registering a gain of 15,017.9 points (up 22.6%).
SUVEN PHARMACEUTICALS net profit fell 56.9% YoY to Rs 534 million for the quarter ended March 2024, compared to a profit of Rs 1,240 million a year ago. Net sales declined 31.5% to Rs 2,529 million during the period as against Rs 3,694 million in January-March 2023.
For the year ended March 2024, SUVEN PHARMACEUTICALS reported 27.0% decrease in net profit to Rs 3,003 million compared to net profit of Rs 4,113 million during FY23. Revenue of the company fell 21.6% to Rs 10,514 million during FY24.
The current Price to earnings ratio of SUVEN PHARMACEUTICALS, based on rolling 12 month earnings, stands at 75.8.
Equitymaster requests your view! Post a comment on "SUVEN PHARMACEUTICALS Plunges 3%; BSE HEALTHCARE Index Up 0.1%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!